Insider Buying: Clene (NASDAQ:CLNN) Director Buys 33,333 Shares of Stock

Clene Inc. (NASDAQ:CLNN) Director David Matlin purchased 33,333 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were purchased at an average cost of $6.50 per share, for a total transaction of $216,664.50. Following the completion of the transaction, the director owned 477,824 shares in the company, valued at approximately $3,105,856. This represents a 7.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Clene Trading Down 1.5%

Clene stock traded down $0.08 during mid-day trading on Tuesday, reaching $5.10. The company’s stock had a trading volume of 277,268 shares, compared to its average volume of 132,371. Clene Inc. has a twelve month low of $2.28 and a twelve month high of $13.50. The business has a 50 day moving average price of $7.54 and a 200-day moving average price of $6.45. The firm has a market cap of $52.68 million, a price-to-earnings ratio of -1.50 and a beta of 0.87.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. On average, equities analysts expect that Clene Inc. will post -5.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Clene

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLNN. Jones Financial Companies Lllp bought a new stake in Clene during the 3rd quarter valued at $29,000. Jane Street Group LLC bought a new position in shares of Clene in the second quarter worth $47,000. Lunt Capital Management Inc. increased its holdings in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the period. Finally, Scoggin Management LP raised its stake in shares of Clene by 42.8% during the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares in the last quarter. 23.28% of the stock is owned by institutional investors.

Clene News Roundup

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Clene announced the FDA has granted an in‑person Type C meeting later this quarter and released additional CNM‑Au8 biomarker data that the company says could support a potential NDA filing — a clear regulatory catalyst that could derisk the development program if the meeting goes well. Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
• Neutral Sentiment: Reported short‑interest figures for January appear to show 0 shares and a days‑to‑cover of 0.0 — likely a reporting/data anomaly rather than a meaningful change in market positioning; don’t rely on that data point alone.
• Negative Sentiment: Major shareholder Chidozie Ugwumba has been actively selling in early January, including a 32,705‑share sale (avg. ~$5.50) disclosed Jan. 12 and multiple other disposals totaling tens of thousands of shares across the first two weeks of January. The sales have reduced his stake (one filing shows a ~4.41% decrease after the 32,705‑share trade), which can pressure the stock and signal liquidity needs or portfolio rebalancing. Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 3,195 Shares of Stock

Wall Street Analysts Forecast Growth

CLNN has been the subject of a number of research reports. UBS Group restated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Benchmark reissued a “buy” rating on shares of Clene in a report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Friday. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of Clene in a research report on Friday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).